Quarterly net revenues of $155 million, up 22% year-over-year, with record 4,113 active patients on therapy as of September 30, 2024
FDA approves Optune Lua® for the treatment of metastatic non-small cell lung cancer
https://www.biospace.com/press-releases/novocure-reports-third-quarter-2024-financial-results
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.